Which act grants and tax incentives to develop targeted drugs for patient populations under 200,000?

• A. Orphan Drug Act 1983
• B. FDA Act 1988
• C. Prescription Drug User Fee Act 1992
• D. Dietary Supplement Health Act 1994

Answer: (A)

The concept being tested is how policy creates incentives to develop drugs for very small patient populations. For conditions affecting fewer than 200,000 people in the United States, the Orphan Drug Act of 1983 was designed to encourage research and development by making it economically more feasible. It offers valuable incentives such as tax credits for qualified clinical testing, potential grants, and, importantly, seven years of market exclusivity after approval for the orphan indication. This combination reduces the financial risk and increases potential return when the patient base is tiny, which is exactly why it’s used for targeted drugs addressing rare diseases. The other options don’t provide this specific mix of orphan designation and financial incentives: they relate to speeding FDA review through user fees, regulate dietary supplements, or refer to different regulatory provisions that don’t focus on rare-disease drug development.